Breakthrough Results in Lymphoma Treatments with Odronextamab
Odronextamab monotherapy has demonstrated full responses in patients with previously untreated follicular lymphoma, as indicated by initial findings from the safety lead-in phase of the confirmatory Phase 3 OLYMPIA-1 trial. This highlights the potential of odronextamab in earlier lines of treatment across various lymphoma types.
Significant Findings from the OLYMPIA-1 Trial
The OLYMPIA-1 trial consists of a non-randomized safety run-in followed by a randomized efficacy assessment comparing odronextamab monotherapy with rituximab and standard chemotherapy regimens. Preliminary results from Part 1 of the trial showed that all 12 evaluable patients achieved complete responses by week 12. In contrast, historical data indicated an objective response rate of 89% with standard treatment, with only a 67% complete response rate.
The safety profile was also encouraging, with no dose-limiting toxicity reported. Among patients evaluable for safety, common adverse events included cytokine release syndrome (62%), diarrhea (46%), and rash (39%). Despite some infections, there were no severe cases of tumor lysis syndrome or neurotoxicity associated with odronextamab.
Initial Data Implies Promising Outlook for Patients
According to Elizabeth Brém, Associate Clinical Professor, the data from the OLYMPIA-1 trial may signify a potential shift in treatment paradigms for previously untreated follicular lymphoma patients. The trial not only aims to introduce a novel, chemotherapy-free option but also underscores the remarkable effectiveness demonstrated by odronextamab in late-line therapies.
Durability in Diffuse Large B-Cell Lymphoma (DLBCL)
In another presentation, the primary analysis from the ELM-1 trial revealed substantial efficacy in patients with DLBCL who had progressed following CAR-T therapy. Results indicated a 48% overall response rate, with 32% achieving complete remission. Patients continued to show durable responses over a follow-up period of up to 16 months, showcasing the resilience of the treatment.
Notably, the response rates were observed even in patients with high-risk features, including those refractory to previous treatments. With a median duration of response exceeding 15 months and median progression-free survival of approximately five months, these findings enhance the understanding of odronextamab's therapeutic potential in difficult cases.
Encouraging Developments for Relapsed/Refractory Diseases
Matthew Matasar, Chief of Blood Disorders at Rutgers Cancer Institute, underlined the unmet need for effective treatments in patients with DLBCL post-CAR-T therapy, emphasizing that odronextamab may fill a significant gap in therapeutic options.
High Efficacy in Marginal Zone Lymphoma
Further results from the ELM-2 trial presented encouraging outcomes for patients with relapsed/refractory marginal zone lymphoma (MZL). Examining a cohort of heavily pretreated patients, the trial reported a remarkable 77% overall response rate, with all responders achieving complete remission.
These findings were based on a median follow-up duration of eleven months, during which no medians for duration of response or survival were reached, suggesting potentially transformative implications for this patient group with limited treatment options.
Adverse Events and Safety Considerations
The safety profile for these patients indicated a high incidence of treatment-emergent adverse events, with 83% experiencing grade three or higher events. Despite the adverse effects, the responses highlight the potential of odronextamab in managing challenging lymphoma presentations.
About Odronextamab and Regulatory Perspectives
Odronextamab has attained approval in the European Union as Ordspono™ for treating relapsed or refractory follicular lymphoma and DLBCL after multiple lines of systemic therapy. It is important to note that its safety and efficacy remain under consideration by various regulatory authorities, including plans for resubmission to the U.S. regulatory bodies in the near future.
The ongoing investigation across various clinical trials, such as OLYMPIA, ELM-1, and ELM-2, demonstrates a strong commitment to exploring the full potential of odronextamab in diverse therapy settings.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a renowned biotechnology firm dedicated to the discovery and development of innovative therapeutics for patients battling severe diseases. The company is leveraging over three decades of specialized experience in biology to address blood cancers and other challenging medical conditions.
For press inquiries or further information, the contact details are as follows:
Contacts
Media Relations
Tammy Allen
Tel: +1 914-306-2698
tammy.allen@regeneron.com
Investor Relations
Mark Hudson
Tel: +1 914-847-3482
mark.hudson@regeneron.com
Frequently Asked Questions
What is odronextamab?
Odronextamab is a CD20xCD3 bispecific antibody designed to activate T cells against cancer cells, particularly in B-cell malignancies.
What were the results of the OLYMPIA-1 trial?
Initial results indicated complete responses in all evaluable patients with untreated follicular lymphoma, suggesting strong efficacy.
How does odronextamab compare to standard treatments?
Odronextamab demonstrated a higher complete response rate than standard regimens, positioning it as a potentially revolutionary option.
Are there any safety concerns with odronextamab?
Adverse events were noted, including cytokine release syndrome, but overall the safety profile appears manageable.
What is the future of odronextamab in regulatory terms?
The U.S. regulatory resubmission is expected soon, with ongoing investigations into its efficacy and safety across various lymphoma types.
